Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

Key Inclusion Criteria: 1. Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology; 2. Positive antinuclear antibodies (ANA); 3. Activity Index (SLEDAI) score must be 6-11 points, inclusive; 4. Stable dose of prednisone (\<30mg/d) for at least one month ; 5. Active mild to moderate SLE activity as demonstrated by British Isles Lupus Assessment Group Index (BILAG); 6. Males or females between 18 and 65 years old; 7. Weight of 45 kg or greater. Key Exclusion Criteria: 1. Active Severe Lupus as defined by BILAG Index Level A or two or more of Level B in any body system/organ; 2. Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections; 3. Presence of active central nervous system (CNS) disease requiring treatment; 4. Subjects with active, severe SLE disease activity which involves the renal system; 5. Substance abuse or dependence; 6. History of malignant cancer within the last 5 years; 7. Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion; 8. Subjects received any live vaccination within the 30 days prior to Visit 2; 9. Subjects received intravenous immunoglobulin (IVIg) or,plasmapheresis,or High dose prednisone or equivalent (\> 100 mg/day) within 90 days prior to Visit 2; 10. Subjects who have had therapy with cyclophosphamide within 180 days prior to Visit 2 .